Table 1.

Pooled Adverse Events Reported in Fixed-Dose Phase III Trials With Darifenacin

	Darifenacin
	7.5 mg	15 mg	Placebo
Adverse Event*	(n = 337)	(n = 334)	(n = 388)
Dry mouth	20.2	35.5	8.2
Constipation	14.8	21.3	6.2
Dyspepsia	2.7	8.4	2.6
Abdominal pain	2.4	3.9	0.5
Nausea	2.7	1.5	1.5
Diarrhea	2.1	0.9	1.8
Urinary tract infection	4.7	4.5	2.6
Dizziness	0.9	2.1	1.3
Asthenia	1.5	2.7	1.3
Dry eyes	1.5	2.1	0.5

Values are percentages.

^*≥ 2% for any group.

Data from Novartis Pharmaceutical Corporation (data on file); pooled studies 1001, 1002, 1041.